Cellectar Biosciences, Inc. (CLRB)
$2.55-$0.01 (-0.39%) Today
Latest CLRB Insider Trades
Jarrod Longcor - OfficerOpen-market purchase$25K
Jarrod Longcor - OfficerJarrod Longcor - Officer
James V. Caruso - OfficerJames V. Caruso - OfficerJames V. Caruso - OfficerJames V. Caruso - OfficerJarrod Longcor - OfficerCellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 10 | 627,500 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
16 Form 4 filings on record, the earliest from Jul 3, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Stefan Loren | Grant or award | Stock option (right to buy) | 15,000 | $0.00 | - | |
| Chad J. Kolean - Officer | Grant or award | Stock option (right to buy) | 92,000 | $0.00 | - | |
| Frederick W. Driscoll - Director | Grant or award | Stock option (right to buy) | 25,000 | $0.00 | - | |
| Asher Chanan-Khan - Director | Grant or award | Stock option (right to buy) | 25,000 | $0.00 | - | |
| James V. Caruso - Officer | Grant or award | Stock option (right to buy) | 250,000 | $0.00 | - | |
| Andrew Gu - Director | Grant or award | Stock option (right to buy) | 25,000 | $0.00 | - | |
| Jarrod Longcor - Officer | Grant or award | Stock option (right to buy) | 118,000 | $0.00 | - | |
 Douglas J. Swirsky - Director | Grant or award | Stock option (right to buy) | 37,500 | $0.00 | - | |
| John Neis - Director | Grant or award | Stock option (right to buy) | 25,000 | $0.00 | - | |
| Stefan Loren | Grant or award | Stock option (right to buy) | 15,000 | $0.00 | - | |
| Jarrod Longcor - Officer | Open-market purchase | Common Stock | 8,680 | $2.88 | $25K | |
| Jarrod Longcor - Officer | Open-market purchase | Warrants | 26,040 | $0.01 | $260 | |
| James V. Caruso - Officer | Open-market purchase | Common Stock | 8,680 | $2.88 | $25K | |
| James V. Caruso - Officer | Open-market purchase | Warrants | 26,040 | $0.01 | $260 | |
| John Neis - Director | Open-market sale | Common Stock | 198 | $3.70 | $732 | |
| James V. Caruso - Officer | Open-market purchase | Common Stock | 10,000 | $4.99 | $50K | |
| James V. Caruso - Officer | Open-market purchase | Warrants | 10,000 | $0.01 | $100 | |
| Jarrod Longcor - Officer | Open-market purchase | Common Stock | 10,000 | $4.99 | $50K | |
| Jarrod Longcor - Officer | Open-market purchase | Warrants | 10,000 | $0.01 | $100 | |
| Chad J. Kolean - Officer | Open-market purchase | Common Stock | 5,000 | $4.99 | $25K | |
| Chad J. Kolean - Officer | Open-market purchase | Warrants | 5,000 | $0.01 | $50 |
Cellectar Biosciences, Inc. (CLRB) had 10 insider filings in the last 90 days, with the most recent on 2026-07-11. The full record for CLRB runs to 16 Form 4 filings, the earliest from 2025-07-03. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CLRB were filed in the last 90 days. 10 purchases are on record for this company.
No insider sales of CLRB were filed in the last 90 days. 1 sale is on record for this company.
This page tracks CLRB Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CLRB to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
